RecruitingNCT03004326
Clinical Transcriptomics in Systemic Vasculitis (CUTIS)
Studying Anti-neutrophil cytoplasmic antibody-associated vasculitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Peter Merkel
- Principal Investigator
- Robert Micheletti, MDUniversity of Pennsylvania
- Enrollment
- 50 enrolled
- Eligibility
- 5 years · All sexes
- Timeline
- 2017 – 2028
Study locations (10)
- University of California, Los Angeles, Los Angeles, California, United States
- Boston University School of Medicine, Boston, Massachusetts, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- Oregon Health & Science University, Portland, Oregon, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- University of Utah, Salt Lake City, Utah, United States
- University of Virginia, Charlottesville, Virginia, United States
- St. Joseph's Healthcare, Hamilton, Ontario, Canada
- University of Toronto Mount Sinai Hospital, Toronto, Ontario, Canada
Collaborators
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · National Center for Advancing Translational Sciences (NCATS) · Office of Rare Diseases Research (ORDR)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03004326 on ClinicalTrials.govOther trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07556484Pharmacokinetics Of Emulsified Avacopan Applied By NG TubeMayo Clinic
- RECRUITINGEARLY PHASE1NCT07507201Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune DiseaseThe Children's Hospital of Zhejiang University School of Medicine
- RECRUITINGNCT07258524PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated VasculitisUniversity of Edinburgh
- RECRUITINGPHASE1NCT07315087CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune DiseasesInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07160608Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated VasculitisAlexion Pharmaceuticals, Inc.
- RECRUITINGPHASE3NCT06983821Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)Ottawa Hospital Research Institute
- RECRUITINGPHASE3NCT07168161BDB-001 Phase III Trial in ANCA-Associated VasculitisStaidson (Beijing) Biopharmaceuticals Co., Ltd
- RECRUITINGNCT07151521(68)Ga-FAPI PET/CT in Patients With ANCA-associated VasculitisRuijin Hospital
See all trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis →